Platinum Investment Management’s Apogee Therapeutics APGE Stock Holding History

Platinum Investment Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.74M	Hold	58,314	–	–	1.9%	12
2026 Q1	$4.91M	Sell	58,314 -10,898	-16%	-$791K	1.24%	24
2025 Q4	$5.22M	Sell	69,212 -24,516	-26%	-$1.54M	1.21%	27
2025 Q3	$3.72M	Buy	93,728 +7,216	+8%	+$276K	0.24%	46
2025 Q2	$3.76M	Sell	86,512 -9,134	-10%	-$347K	0.25%	41
2025 Q1	$3.57M	Hold	95,646	–	–	0.21%	36
2024 Q4	$4.33M	Sell	95,646 -12,048	-11%	-$614K	0.25%	41
2024 Q3	$6.33M	Sell	107,694 -39,778	-27%	-$1.91M	0.29%	32
2024 Q2	$5.8M	Sell	147,472 -20,406	-12%	-$990K	0.23%	34
2024 Q1	$11.2M	Sell	167,878 -115,805	-41%	-$5.06M	0.45%	28
2023 Q4	$7.93M	Hold	283,683	–	–	0.32%	45
2023 Q3	$6.04M	Buy	+283,683	New	+$6.25M	0.24%	48

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Platinum Investment Management's APGE Position: Q2 2026 in Review

Platinum Investment Management held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 58,314 shares worth $7.74M. The position accounts for 1.9% of the portfolio, ranked #12.

Platinum Investment Management first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. The position peaked at $11.2M in Q1 2024. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Platinum Investment Management held 58,314 shares of Apogee Therapeutics worth $7.74M as of Q2 2026.
Platinum Investment Management left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up 1.9% of Platinum Investment Management's portfolio in Q2 2026, its #12 holding.
Platinum Investment Management first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
Platinum Investment Management's Apogee Therapeutics position peaked at $11.2M in Q1 2024.
288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Platinum Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.